Rapid Micro Biosystems Inc Class A RPID
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPID is a good fit for your portfolio.
News
-
Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024
-
Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024
-
Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum
-
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
-
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
-
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
-
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.93–0.94
- 52-Week Range
- $0.74–1.19
- Bid/Ask
- $0.83 / $0.98
- Market Cap
- $39.82 Mil
- Volume/Avg
- 1,317 / 40,879
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 193
- Website
- https://www.rapidmicrobio.com
Valuation
|
Metric
|
RPID
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.33 |
Price/Sales | 1.78 |
Price/Cash Flow | — |
Price/Earnings
RPID
Financial Strength
|
Metric
|
RPID
|
|---|---|
Quick Ratio | 5.14 |
Current Ratio | 6.34 |
Interest Coverage | — |
Quick Ratio
RPID
Profitability
|
Metric
|
RPID
|
|---|---|
Return on Assets (Normalized) | −29.76% |
Return on Equity (Normalized) | −34.70% |
Return on Invested Capital (Normalized) | −35.17% |
Return on Assets
RPID
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mhmfwpg | Jwwwdf | $185.5 Bil | |
SYK
| Stryker Corp | Qbssxtmtc | Shfzd | $128.2 Bil | |
MDT
| Medtronic PLC | Lvghfmqxk | Nnlsmr | $106.7 Bil | |
BSX
| Boston Scientific Corp | Bdwxntqgx | Grjft | $99.0 Bil | |
DXCM
| DexCom Inc | Lbxpvdsz | Drq | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Ckvrscsh | Nrzhbrv | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Dcmsrzwp | Ytd | $24.9 Bil | |
ALGN
| Align Technology Inc | Xqqzxmd | Fcwqpvt | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Gckswbltb | Bgxjrc | $18.9 Bil | |
PODD
| Insulet Corp | Yrthydbrfn | Kpfrndq | $11.7 Bil |